Spanner

US-based medical device company SRS Medical Systems has secured the CE mark approval for its spanner temporary prostatic stent (STPS) in the European Economic Area (EEA).

The spanner acts as an alternative to indwelling (Foley) and intermittent urinary catheters for male patients with bladder outlet obstruction (BOO).

Related Company Profiles

View all

The internally placed device allows the patient to relieve their bladders without being conscious of the device presence.

SRS Medical CEO Lee Brody said: "The Spanner is proven to have significant impact on medical outcomes, and often has a transformational impact on patient quality of life.

"We are excited to receive this approval, and we look forward to working with our European partners to deliver The Spanner to the patients that will benefit from it the most."

See Also:

The US Food and Drug Administration (FDA) approved STPS is a Class III medical device designed to maintain urine flow and enable voluntary urination in male patients with lower urinary tract symptoms (LUTS).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The device features two anchors and a silicone tube which minimises resistance in the bladder neck and prostatic urethra without stenting the external sphincter.

"The Spanner is proven to have significant impact on medical outcomes, and often has a transformational impact on patient quality of life."

The application of the spanner does not require anesthesia.

The spanner, apart from treating BOO, also reduces infection risk and medical complication in patients who will be subjected to benign prostatic hyperplasia (BPH) treatment.

It has the ability to predict a potential BPH treatment outcome in the patients.

The spanner results long-term relief for patients who are unfit to undergo prostate procedures.

Image: SRS Medical’s Spanner Temporary Prostatic Stent. Photo: courtesy of Business Wire.